Integrin Alpha 7 (ITGA7) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) – Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Alpha 7 (ITGA7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)

The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Integrin Alpha 7 (ITGA7) Overview 5

Therapeutics Development 6

Integrin Alpha 7 (ITGA7) - Products under Development by Stage of Development 6

Integrin Alpha 7 (ITGA7) - Products under Development by Therapy Area 7

Integrin Alpha 7 (ITGA7) - Products under Development by Indication 8

Integrin Alpha 7 (ITGA7) - Pipeline Products Glance 9

Early Stage Products 9

Integrin Alpha 7 (ITGA7) - Products under Development by Companies 10

Integrin Alpha 7 (ITGA7) - Therapeutics Assessment 12

Assessment by Monotherapy/Combination Products 12

Assessment by Mechanism of Action 13

Assessment by Molecule Type 14

Integrin Alpha 7 (ITGA7) - Drug Profiles 16

Stryka-232 - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

Stryka-234 - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

Stryka-425 - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

Stryka-516 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

Stryka-533 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Stryka-969 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Stryka-978 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

StrykaPro-1 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Appendix 24

Methodology 24

Coverage 24

Secondary Research 24

Primary Research 24

Expert Panel Validation 24

Contact Us 24

Disclaimer 25

List of Tables

List of Tables

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of Products under Development by Indication, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Products under Development by Companies, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 12

Number of Products by Stage and Mechanism of Action, H2 2016 13

Number of Products by Stage and Molecule Type, H2 2016 15

List of Figures

List of Figures

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of Products under Development by Indication, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 12

Number of Products by Stage and Mechanism of Actions, H2 2016 13

Number of Products by Molecule Types, H2 2016 14

Number of Products by Stage and Molecule Type, H2 2016 14

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports